AAAAAA

   
Results: 1-9 |
Results: 9
Advances in the treatment of polycystic ovary syndrome
Authors: Moghetti, P
Citation: P. Moghetti, Advances in the treatment of polycystic ovary syndrome, EXPERT OP I, 10(9), 2001, pp. 1631-1640
Power spectral analysis of heart rate in hypothyroidism
Authors: Cacciatori, V Gemma, ML Bellavere, F Castello, R De Gregori, ME Zoppini, G Thomaseth, K Moghetti, P Muggeo, M
Citation: V. Cacciatori et al., Power spectral analysis of heart rate in hypothyroidism, EUR J ENDOC, 143(3), 2000, pp. 327-333
Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients - The Verona Diabetes Study
Authors: Muggeo, M Bonadonna, RC Zoppini, G Moghetti, P Bonora, E Verlato, G Brun, E
Citation: M. Muggeo et al., Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients - The Verona Diabetes Study, DIABET CARE, 23(1), 2000, pp. 45-50
Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: Evidence that serum PSA is a marker of androgen action in women
Authors: Negri, C Tosi, F Dorizzi, R Fortunato, A Spiazzi, GG Muggeo, M Castello, R Moghetti, P
Citation: C. Negri et al., Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: Evidence that serum PSA is a marker of androgen action in women, J CLIN END, 85(1), 2000, pp. 81-84
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial
Authors: Moghetti, P Tosi, F Tosti, A Negri, C Misciali, C Perrone, F Caputo, M Muggeo, M Castello, R
Citation: P. Moghetti et al., Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial, J CLIN END, 85(1), 2000, pp. 89-94
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
Authors: Moghetti, P Castello, R Negri, C Tosi, F Perrone, F Caputo, M Zanolin, E Muggeo, M
Citation: P. Moghetti et al., Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation, J CLIN END, 85(1), 2000, pp. 139-146
Leptin concentration in newborns' cord blood: relationship to gender and growth-regulating hormones
Authors: Maffeis, C Moghetti, P Vettor, R Lombardi, AM Vecchini, S Tato, L
Citation: C. Maffeis et al., Leptin concentration in newborns' cord blood: relationship to gender and growth-regulating hormones, INT J OBES, 23(9), 1999, pp. 943-947
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist
Authors: Moghetti, P Castello, R Zamberlan, N Rossini, M Gatti, D Negri, C Tosi, F Muggeo, M Adami, S
Citation: P. Moghetti et al., Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist, J CLIN END, 84(4), 1999, pp. 1250-1254
Authors' response: Spironolactone but not flutamide administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist
Authors: Moghetti, P Castello, R Zamberlan, N Rossini, M Gatti, D Negri, C Tosi, F Muggeo, M Adami, S
Citation: P. Moghetti et al., Authors' response: Spironolactone but not flutamide administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist, J CLIN END, 84(12), 1999, pp. 4747-4747
Risultati: 1-9 |